DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...
DUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Hosted on MSN1d
GSK lowered to hold by Jefferies, valuation disconnect citedJefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
The major players in the market are Hisamitsu Pharmaceuticals, Bayer AG, Novartis AG, Galderma Holding SA, GlaxoSmithKline PLC, Johnson & Johnson Private Limited, Bausch Health Companies Inc., Cipla ...
The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback